Valo Therapeutics Secures €19 Million for Cancer Immunotherapy
Valo Therapeutics Secures Significant Investment for Cancer Trials
Valo Therapeutics Oy has announced a successful financing round amounting to €19 million to propel the clinical development of its cutting-edge immune therapy designed for cancer treatment. This endeavor is a significant step towards advancing the company's mission of improving patient outcomes in oncology.
Investment Details and Strategic Partners
The investment round was co-led by notable partners Indaco Venture Partners and CDP Venture Capital SGR. They have been instrumental in raising €13 million towards this initiative, complemented by an additional €6 million from Australian investors. This collaborative effort highlights the strong backing for innovative therapeutics in the cancer treatment landscape.
Development of PeptiCRAd and Clinical Trials
Valo Therapeutics focuses on a unique immunotherapy platform known as PeptiCRAd, which utilizes tumor antigen-coated oncolytic virus candidates to enhance anti-tumor immune responses. The recent funding will help expand and complete the Phase 1B clinical study, further validating the therapeutic potential of PeptiCRAd in treating solid tumors.
International Collaboration for Clinical Trials
The planned clinical trials will span across several countries, namely Italy, Australia, and Germany, showcasing an international commitment to the research and treatment of cancer. This multi-country approach not only accelerates the clinical trials but also strengthens collaborations between various research institutions.
Creating a New Operating Entity in Italy
A portion of the raised funds will be channeled into establishing Valo Therapeutics Italy Srl. This new operational arm will be based in Naples, set to facilitate patient enrollment and treatment initiatives, undertake large-scale manufacturing, and collaborate closely with local research institutions. This initiative emphasizes Valo's commitment to advancing cancer therapy solutions in the Southern Italian region.
Comments from Valo's Leadership
David Hinton, Chair of Valo Therapeutics, expressed enthusiasm about securing investor backing, which enables the company to execute vital clinical trials in Italy and Australia. He emphasized the long-term vision of scaling up developments, paving the way for future larger Phase 2 clinical trials.
Trust in Innovative Therapeutics
Giovanni Rizzo from Indaco Venture Partners highlighted the potential of Valo's precision medicine and advanced platform technology. By generating robust immune responses, PeptiCRAd holds promise in reshaping therapeutic options for patients with previously untreatable solid tumors.
Impact on the Biotech Ecosystem
Francesca Ottier of CDP Venture Capital pointed out the significance of this investment in enhancing the biotech innovation ecosystem within Italy. The establishment of a new research and development center in Naples marks an important milestone in fostering local talent while advancing innovative solutions for cancer treatment.
Valo Therapeutics’ Commitment to Research and Development
Valo Therapeutics remains focused on advancing its proprietary development projects. Their flagship platform, PeptiCRAd, is expected to greatly impact the immuno-oncology space. This innovative strategy aims to leverage oncolytic adenoviruses for activating comprehensive anti-tumor immunity.
Moreover, the company plans to develop PeptiCHIP, an innovative tool for swift and accurate neoantigen identification from small tumor biopsies, further streamlining therapeutic processes in personalized medicine.
About Valo Therapeutics Oy
Valo Therapeutics Oy (ValoTx) is dedicated to devising groundbreaking immunotherapy solutions. Established from research conducted by Professor Vincenzo Cerullo, ValoTx fosters a culture of innovation to enhance treatment methodologies against cancer.
Frequently Asked Questions
What is Valo Therapeutics working on?
Valo Therapeutics is developing an innovative immune therapy called PeptiCRAd, designed to treat cancer patients by enhancing their immune responses to tumors.
How much funding has Valo Therapeutics secured?
The company recently secured a total of €19 million in investment funding to support its clinical trials and development efforts.
Where will the clinical trials take place?
The planned clinical trials are set to occur in Italy, Australia, and Germany, showcasing international collaboration in cancer research.
What does PeptiCRAd aim to accomplish?
PeptiCRAd aims to activate strong immune responses against solid tumors, potentially transforming treatment options for patients with difficult-to-treat cancers.
What is the significance of the new operating entity in Italy?
The establishment of Valo Therapeutics Italy Srl will facilitate patient treatment and research initiatives, significantly contributing to the biomedical sector in Southern Italy.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
